Пищевая аллергия у детей: вызовы терапии и стандартизация исходов

Актуальность. Пищевая аллергия (ПА) является серьезной проблемой здравоохранения, особенно среди детей, с возрастающей распространенностью. Она оказывает значительное влияние на качество жизни пациентов и их семей из-за необходимости избегать аллергенов и рисков тяжелых аллергических реакций, таких как анафилаксия. Несмотря на активные исследования, основное лечение по-прежнему заключается в элиминационной диете, что ограничивает возможности пациентов и требует поиска новых терапевтических решений.

Цель обзора. Настоящий обзор направлен на обобщение современных методов лечения пищевой аллергии, рассмотрение актуальных проблем при оценке эффективности интервенций и обсуждение важности стандартизации исходов клинических исследований для улучшения их сопоставимости и практической значимости.

Содержание. Обзор включает обсуждение современных терапевтических подходов к лечению пищевой аллергии, таких как оральная, эпикутанная и сублингвальная иммунотерапии, которые демонстрируют положительные результаты в достижении толерантности к аллергенам. Особое внимание уделяется проблемам безопасности этих методов, особенно у детей, что подчеркивает необходимость дальнейших исследований. Кроме того, рассматриваются перспективы использования биологических препаратов, таких как омализумаб, в терапии пищевой аллергии. Также обсуждаются сложности в выборе и стандартизации конечных точек в клинических исследованиях, где большинство фокусируется на десенсибилизации и иммунологических показателях, тогда как такие пациент-ориентированные исходы, как качество жизни, остаются недостаточно изученными. Внедрение «наборов основных исходов» представляет важный шаг для улучшения сопоставимости данных и формирования более объективной базы для клинических рекомендаций.

Выводы. Обзор подчеркивает значительный прогресс в лечении пищевой аллергии, однако отмечает необходимость дальнейших исследований для обеспечения безопасности новых терапий, особенно для детей. Стандартизация исходов в клинических испытаниях играет ключевую роль для улучшения качества и сопоставимости исследований, что, в свою очередь, будет способствовать разработке более эффективных клинических рекомендаций и улучшению качества жизни пациентов. 

1. Sicherer S.H., Sampson H.A. Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018; 141 (1): 41–58.

2. Muraro A., de Silva D., Halken S., et al. Managing food allergy: GA(2)LEN guideline 2022. World Allergy Organ J. 2022; 15 (9): 100687.

3. Yamamoto-Hanada K., Pak K., Iwamoto S., Konishi M., Saito-Abe M., Sato M., Miyaji Y., Mezawa H., Nishizato M., Yang L., Kumasaka N., Ohya Y.; Japan Environment and Children's Study (JECS) Group. Parental stress and food allergy phenotypes in young children: A National Birth Cohort (JECS). Allergy. 2024 Jul;79(7):1881-1892. https://doi.org/10.1111/all.16035.

4. Lloyd M., Patel N., Munblit D., Tang M.L.K. Endpoints and Outcomes After Immunotherapy for Food Allergy: What Is Meaningful for Patients? J Allergy Clin Immunol Pract. 2023; 11 (4): 998–1007.

5. Williamson P.R., Altman D.G., Bagley H., et al. The COMET Handbook: version 1.0. Trials. 2017; 18 (Suppl 3): 280.

6. Kim J.F., McCleary N., Nwaru B.I., Stoddart A., Sheikh A. Diagnostic Accuracy, Risk Assessment, and Cost-effectiveness of Component-resolved Diagnostics for Food Allergy: A Systematic Review. Allergy. 2018; 73 (8): 1609–1621.

7. Contributors W., Joint Task Force on Practice Parameters R. Anaphylaxis — a 2020 Practice Parameter Update, Systematic Review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Analysis. Journal of Allergy and Clinical Immunology. 2020; 145 (4): 1082–1123.

8. Spolidoro G.C.I., Amera Y.T., Ali M.M., et al. Frequency of food allergy in Europe: An updated systematic review and meta-analysis. Allergy. 2023; 78 (2): 351–368.

9. Panesar S.S., Javad S., Silva Dd, et al. The Epidemiology of Anaphylaxis in Europe: A Systematic Review. Allergy. 2013; 68 (11): 1353–1361.

10. Wang Y., Allen K.J., Suaini N.H.A., McWilliam V., Peters R.L. The Global Incidence and Prevalence of Anaphylaxis in Children in the General Population: A Systematic Review. Allergy. 2019; 74 (6): 1063–1080.

11. Tsakok T., Marrs T., Mohsin M., et al. Does Atopic Dermatitis Cause Food Allergy? A systematic Review. Journal of Allergy and Clinical Immunology. 2016; 137 (4): 1071–1078.

12. Suaini N.H.A., Wang Y., Soriano V.X., et al. Genetic Determinants of Paediatric Food Allergy: A Systematic Review. Allergy. 2019; 74 (9): 1631–1648.

13. Skjerven H.O., Lie A., Vettukattil R., et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2022; 399 (10344): 2398–2411.

14. Silva Dd, Geromi M., Halken S., et al. Primary Prevention of Food Allergy in Children and Adults: Systematic Review. Allergy. 2014; 69 (5): 581–589.

15. Vazquez-Ortiz M., Angier E., Blümchen K., et al. Understanding the Challenges Faced by Adolescents and Young Adults With Allergic Conditions: A Systematic Review. Allergy. 2020; 75 (8): 1850–1880.

16. Epstein-Rigbi N., Goldberg M.R., Levy M.B., Nachshon L., Elizur A. Quality of Life of Children Aged 8-12 Years Undergoing Food Allergy Oral Immunotherapy: Child and Parent Perspective. Allergy. 2020; 75 (10): 2623–2632.

17. Scurlock A.M., Jones S.M. Advances in the Approach to the Patient With Food Allergy. Journal of Allergy and Clinical Immunology. 2018; 141 (6): 2002–2014.

18. Muraro A., Agache I., Clark A., et al. EAACI Food Allergy and Anaphylaxis Guidelines: Managing Patients With Food Allergy in the Community. Allergy. 2014; 69 (8): 1046–1057.

19. Crestani E., Harb H., Charbonnier L.-M., et al. Untargeted Metabolomic Profiling Identifies Disease-Specific Signatures in Food Allergy and Asthma. Journal of Allergy and Clinical Immunology. 2020; 145 (3): 897–906.

20. Mortz C.G. A Randomized, Double-blind Placebo-controlled Study on the Efficacy of Omalizumab on Food Allergy Threshold in Children With Severe Food Allergy. Allergy. 2024; 79 (4): 964–976.

21. Sampath V., Sindher S., Alvarez-Pinzon A.M., Nadeau K. Can Food Allergy Be Cured? What Are the Future Prospects? Allergy. 2019; 75 (6): 1316–1326.

22. Greenhawt M., Sindher S.B., Wang J., et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med. 2023; 388 (19): 1755–1766.

23. Leung D.Y., Guttman-Yassky E. Deciphering the Complexities of Atopic Dermatitis: Shifting Paradigms in Treatment Approaches. Journal of Allergy and Clinical Immunology. 2014; 134 (4): 769–779.

24. Narisety S.D., Frischmeyer-Guerrerio P.A., Keet C.A., et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015; 135 (5): 1275–1282 e1-6.

25. Keet C.A., Frischmeyer-Guerrerio P.A., Thyagarajan A., et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012; 129 (2): 448–455, e1-5.

26. Togias A., Cooper S., Acebal M.L., et al. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases — sponsored Expert Panel. Journal of Allergy and Clinical Immunology. 2017; 139 (1): 29–44.

27. Wood R.A., Togias A., Sicherer S.H., et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024; 390 (10): 889–899.

28. Sun H., Como P., Downey L.C., Murphy D., Ariagno R.L., Rodriguez W.J. Infant Formula and Neurocognitive Outcomes: Impact of Study End-Point Selection. Journal of Perinatology. 2015; 35 (10): 867–874.

29. Coleman R.L., Beck J.T., Baranda J., et al. The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials. Oncology. 2021; 99 (7): 444–453.

30. D’Souza A., Hari P., Pasquini M.C., Jacobsen K.K., Flynn K.E. Baseline Patient-Reported Outcomes in Light-Chain Amyloidosis Patients Enrolled on an Interventional Clinical Trial. Amyloid. 2019; 26 (sup1): 87–88.

31. Taylor A.M., Phillips K., Patel K.V., et al. Assessment of Physical Function and Participation in Chronic Pain Clinical Trials: IMMPACT/OMERACT Recommendations. Pain. 2016; 157 (9): 1836–1850.

32. Gianola S., Castellini G., Corbetta D., Moja L. Rehabilitation Interventions in Randomized Controlled Trials for Low Back Pain: Proof of Statistical Significance Often Is Not Relevant. Health and Quality of Life Outcomes. 2019; 17 (1).

33. Gorst S.L., Prinsen C.A., Salcher-Konrad M., Matvienko-Sikar K., Williamson P., Terwee C.B. Methods Used in the Selection of Instruments for Outcomes Included in Core Outcome Sets Have Improved Since the Publication of the COSMIN/COMET Guideline. Journal of Clinical Epidemiology. 2020; 125: 64–75.

34. Kirkham J.J., Altman D.G., Chan A.W., Gamble C., Dwan K., Williamson P. Outcome Reporting Bias in Trials: A Methodological Approach for Assessment and Adjustment in Systematic Reviews. BMJ. 2018: k3802.

35. Ioannidis J.P.A., Caplan A.L., Dal-Ré R. Outcome Reporting Bias in Clinical Trials: Why Monitoring Matters. BMJ. 2017: j408.

36. Schilsky R.L. Moving From Evaluation to Value in Cancer Care. Clinical Cancer Research. 2015; 21 (5): 947–949.

37. Clair C.O.S, Papadopoulos E.J. Considerations in the Assessment of Clinical Benefit With a Focus on Pain: A Regulatory Perspective. Neurotherapeutics. 2020; 17 (3): 770–773.

38. Gargon E., Gurung B., Medley N., et al. Choosing Important Health Outcomes for Comparative Effectiveness Research: A Systematic Review. Plos One. 2014; 9 (6): e99111.

39. Sim K., Mijakoski D., Stoleski S., et al. Outcomes for clinical trials of food allergy treatments. Ann Allergy Asthma Immunol. 2020; 125 (5): 535–542.

40. Rodriguez Del Rio P., Alvaro-Lozano M., Arasi S., et al. Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force. Allergy. 2024; 79 (4): 793–822.

41. Burks A.W., Sampson H.A., Plaut M., Lack G., Akdis C.A. Treatment for food allergy. J Allergy Clin Immunol. 2018; 141 (1): 1–9.

42. Plaut M., Sawyer R.T., Fenton M.J. Summary of the 2008 National Institute of Allergy and Infectious Diseases — US Food and Drug Administration Workshop on Food Allergy Clinical Trial Design. J Allergy Clin Immunol. 2009; 124 (4): 671–678 e1.

43. Chu D.K., Wood R.A., French S., et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019; 393 (10187): 2222–2232.

44. Dunn Galvin A., Fleischer D.M., Campbell D.E., et al. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. J Allergy Clin Immunol Pract. 2021; 9 (1): 216–224 e1.

45. Dunn Galvin A., Lloyd M., Hsiao K.C., Tang M.L.K., PPOIT-001 study team. Long-term benefit of probiotic peanut oral immunotherapy on quality of life in a randomized trial. J Allergy Clin Immunol Pract. 2021; 9 (12): 4493–4495 e1.

46. Loke P., Orsini F., Lozinsky A.C., et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. Lancet Child Adolesc Health. 2022; 6 (3): 171–184.

47. Schmitt J., Apfelbacher C., Spuls P.I., et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2015; 135 (1): 24–30.

48. Williams H.C., Schmitt J., Thomas K.S., et al. The HOME Core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022; 149 (6): 1899–1911.

49. Schmitt J., Langan S., Deckert S., et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013; 132 (6): 1337–1347.

50. Chalmers J.R., Simpson E., Apfelbacher C.J., et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016; 175 (1): 69–79.

51. Collaborators C., Ma C., Schoepfer A.M., et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022; 149 (2): 659–670.

52. Demidova A., Drewitz K.P., Kimkool P., et al. Core Outcome Set for IgE-mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study ‘COMFA’. Allergy. 2024; 79 (4): 977–989.

53. Cohen C.G., Zhao W.W., Ke D., et al. Elevated Cow’s Milk-Specific IgE Levels Prior to Oral Immunotherapy Decrease the Likelihood of Reaching the Maintenance Dose. J Allergy Clin Immunol Pract. 2022; 10(1): 215–221 e2.

54. Maeda M., Imai T., Ishikawa R., et al. Effect of oral immunotherapy in children with milk allergy: The ORIMA study. Allergol Int. 2021; 70 (2): 223–228.

55. Palosuo K., Karisola P., Savinko T., Fyhrquist N., Alenius H., Makela M.J. A Randomized, Open-Label Trial of Hen’s Egg Oral Immunotherapy: Efficacy and Humoral Immune Responses in 50 Children. J Allergy Clin Immunol Pract. 2021; 9 (5): 1892–1901 e1.

56. Fleischer D.M., Greenhawt M., Sussman G., et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019; 321 (10): 946–955.

57. Takaoka Y., Maeta A., Takahashi K., et al. Effectiveness and Safety of Double-Blind, Placebo-Controlled, Low-Dose Oral Immunotherapy with Low Allergen Egg-Containing Cookies for Severe Hen’s Egg Allergy: A Single-Center Analysis. Int Arch Allergy Immunol. 2019; 180 (4): 244–249.